Last checked at 2 Jul 2021 10:28
For immediate release | 2 July 2021 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Block Listing Six Monthly Return
Name of applicant: | ALLIANCE PHARMA PLC | |||
Names of schemes: | a) The Alliance Pharma plc Approved Share Option Plan 2005 b) The Alliance Pharma plc Share Option Plan 2006 c) The Alliance Pharma plc Company Share Option Plan 2015 | |||
Period of return: | From: | 28 December 2020 | To: | 28 June 2021 |
Number of securities originally admitted at date of admission: | 25,000,000 ordinary shares of 1p each 28 June 2017 | |||
Balance of unallotted securities under schemes from previous return: | a) 293,372 b) 5,266,622 c) 13,265,746 | |||
Plus: The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for): | a) Nil b) Nil c) Nil | |||
Less: Number of securities issued/allotted under schemes during period: | a) 258,052 b) 317,909 c) 1,816,189
| |||
Equals: Balance under schemes not yet issued/allotted at end of period: | d) 35,320 e) 4,948,713 f) 11,449,557 | |||
Name of contact: | Chris Chrysanthou, Company Secretary |
Telephone number of contact: | Tel. +44 (0)1249 705166 |
For further information:
Alliance Pharma plc | + 44 (0)1249 466966 |
Peter Butterfield, Chief Executive Officer | |
Andrew Franklin, Chief Financial Officer | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0)20 7466 5000 |
Mark Court / Sophie Wills / Hannah Ratcliff | |
Numis Securities Limited | + 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Oliver Steele | |
Corporate Broking: James Black |
Investec Bank plc | + 44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams | |
Corporate Broking: Patrick Robb |
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com